ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
LoQus23 Therapeutics has emerged from stealth with about $15 million in seed financing from Novartis Venture Fund and Dementia Discovery Fund to develop small-molecule drugs for neurodegenerative diseases. The British start-up is focused on a class of genetic conditions called triplet repeat diseases, which include Huntington’s disease and myotonic dystrophy type 1. LoQus23 will target DNA mismatch repair proteins to slow the course of these degenerative conditions.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X